JE
ELDN icon

JMAC Enterprises’s Eledon Pharmaceuticals ELDN Stock Holding History

JMAC Enterprises’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-58,041
Closed -$239K – 125
2024
Q4 		$239K Hold
58,041
– – 0.04% 155
2024
Q3 		$145K Hold
58,041
– – 0.02% 177
2024
Q2 		$153K Hold
58,041
– – 0.03% 172
2024
Q1 		$120K Hold
58,041
– – 0.02% 166
2023
Q4 		$104K Hold
58,041
– – 0.02% 168
2023
Q3 		$79.5K Sell
58,041
-22,000
-27% -$29.4K 0.02% 159
2023
Q2 		$110K Buy
80,041
+25,503
+47% +$53.2K 0.03% 169
2023
Q1 		$129K Hold
54,538
– – 0.03% 175
2022
Q4 		$124K Hold
54,538
– – 0.03% 172
2022
Q3 		$151K Hold
54,538
– – 0.04% 171
2022
Q2 		$133K Hold
54,538
– – 0.03% 174
2022
Q1 		$215K Hold
54,538
– – 0.05% 170
2021
Q4 		$216K Buy
+54,538
New +$276K 0.05% 165

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

JMAC Enterprises's ELDN Position: Q1 2025 in Review

JMAC Enterprises sold out of Eledon Pharmaceuticals (ELDN) in Q1 2025, closing a stake of 58,041 shares — an estimated $239K sold.

JMAC Enterprises first reported a position in ELDN in Q4 2021 and held it in 13 quarters. The position peaked at $239K in Q4 2024. 83 funds tracked by Wall St. Rank hold ELDN as of Q1 2025.

  • JMAC Enterprises reported no remaining Eledon Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • JMAC Enterprises sold 58,041 Eledon Pharmaceuticals shares in Q1 2025, an estimated $239K.
  • JMAC Enterprises first reported a position in Eledon Pharmaceuticals in Q4 2021 and held it in 13 quarters.
  • JMAC Enterprises's Eledon Pharmaceuticals position peaked at $239K in Q4 2024.
  • 83 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2025.

Based on JMAC Enterprises's 13F filing for Q1 2025, filed 22 Apr 2025.